Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a mechanistic review synthesizing evidence largely from rodent models and cultured systems to propose BMAL1 dysregulation as a unifying mechanism; direct causal evidence in humans is acknowledged as lacking, and clinical data are only consistent with, not proof of, the proposed dual mechanism.
A single-centre cross-sectional study with modest sample size and no control group for adipokine differences; correlational findings are hypothesis-generating rather than causal or practice-defining.
Small, uncontrolled cross-sectional study of a biomarker (SCFA levels) in follicular fluid with no healthy control group, measuring an association rather than a clinical outcome; authors acknowledge need for further studies.
A mixed mechanistic study combining human observational data with a targeted animal model, showing a significant human-animal disconnect that narrows but does not resolve the hypothesis about adiponectin and anxiety in PCOS.
World Journal of Pharmacy and Pharmaceutical Sciences
A systematic review of diagnostic delays and pathophysiology in lean PCOS that synthesizes clinical trials and mechanistic insights, but reports no primary trial data, effect sizes, or comparative outcomes to support clinical decision-making.
World Journal of Pharmacy and Pharmaceutical Sciences
This is a systematic review that synthesizes existing evidence on lean PCOS pathophysiology and diagnostic delays, but reports no primary data, effect sizes, or comparative trial results to support actionable clinical recommendations.
An expert consensus opinion article evaluating the rationale for renaming PCOS to PMOS, supported by a global consensus process and evidence review, rather than reporting new primary data.
A sound cross-sectional study identifying two routine biomarkers (LH/FSH and ALT/AST ratios) that independently discriminate PCOS from idiopathic hirsutism with moderate discriminatory power (AUC 0.728), but requiring prospective validation before clinical adoption.